The company plans to manufacture the listed controlled substances in bulk for sale in bulk to its customers. The company plans to manufacture other controlled substances in bulk which will also be for sale in bulk to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 19, 2012.

Dated: January 6, 2012.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–656 Filed 1–13–12; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to §1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this notice is that on September 12, 2011, Johnson Matthey, Inc., Pharmaceuticals Materials, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma Hydroxybutyric Acid</td>
<td></td>
</tr>
<tr>
<td>(2010)</td>
<td>II</td>
</tr>
<tr>
<td>Amphetamine (1100)</td>
<td>II</td>
</tr>
<tr>
<td>Methylphenidate (1724)</td>
<td>II</td>
</tr>
<tr>
<td>Codeine (9050)</td>
<td>II</td>
</tr>
<tr>
<td>Oxycodeine (9143)</td>
<td>II</td>
</tr>
<tr>
<td>Hydrocodone (9193)</td>
<td>II</td>
</tr>
<tr>
<td>Morphine (9300)</td>
<td>II</td>
</tr>
<tr>
<td>Thebaine (9333)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to manufacture the listed controlled substances in bulk for sale in bulk to its customers. The company plans to manufacture other controlled substances in bulk which will also be for sale in bulk to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 19, 2012.

Dated: January 6, 2012.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–653 Filed 1–13–12; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to §1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this notice is that on August 18, 2011, Johnson Matthey, Inc., Pharmaceuticals Materials, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marijuana (7360)</td>
<td>I</td>
</tr>
<tr>
<td>Tetrahydrocannabinols (7370)</td>
<td>I</td>
</tr>
</tbody>
</table>

The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers.

In reference to drug code 7360 (Marijuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration.

No comments or objections have been received. DEA has authorized the factors in 21 U.S.C. 823(a) and determined that the registration of Austin Pharma LLC, to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Austin Pharma LLC, to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: January 6, 2012.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–663 Filed 1–13–12; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 9, 2011, and published in the Federal Register on August 18, 2011, 76 FR 54101, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug
DEPARTMENT OF JUSTICE

National Institute of Corrections

Solicitation for a Cooperative Agreement—Jail Resource Management: Review and Revision

AGENCY: National Institute of Corrections, U.S. Department of Justice.

ACTION: Solicitation for a Cooperative Agreement.

SUMMARY: The National Institute of Corrections (NIC) is seeking applications for the revision of its Jail Resource Management training program. The project will be for a 9-month period and will be carried out in conjunction with the NIC Jails Division. The awardee will work closely with NIC staff on all aspects of the project. To be considered, applicants must demonstrate, at a minimum, in-depth knowledge of (1) the purpose, functions, and operational complexities of local jails, (2) budget issues common in jails, (3) analysis of jail resource needs, (4) development and presentation of a budget request to appropriate governing bodies, (5) budget management, and (6) the resource constraints faced by many local governments and their jails. Also, the applicant must demonstrate expertise and experience in developing curricula based on adult learning principles, specifically the Instructional Theory into Practice (ITIP) model.

DATES: Applications must be received by 4 p.m. (EDT) on Thursday, February 9, 2012.

ADDRESSES: Mailed applications must be sent to: Director, National Institute of Corrections, 320 First Street NW., Room 5002, Washington, DC 20534. Applicants are encouraged to use Federal Express, UPS, or similar service to ensure delivery by the due date as mail at NIC is sometimes delayed due to security screening.

The cooperative agreement awardee will revise the content of the current program to ensure it is current, accurate, and relevant. The awardee also will ensure that module sequencing is logical and enhances the flow of the program. Finally, the awardee will revise the program’s design to conform to the ITIP model.

Scope of Work: The cooperative agreement awardee will work with NIC staff to ensure that content, module sequencing, and instructional strategies effectively contribute to meeting the program’s goal. To achieve this, the awardee will complete the following activities, at a minimum.

Initial Meeting: The cooperative agreement awardee, with subject matter expert and the curriculum specialist, will attend an initial meeting with the NIC staff for a project overview and preliminary planning. This will take place shortly after the cooperative agreement is awarded. The meeting will last up to one half day and will be conducted via Web conferencing.

Initial curriculum review: The awardee will review and become